causes the biggest mean absolute relative deviation (ARD) of CGM from BG, among the 3 sources of error (12.8% mean ARD caused by the calibration error compared to 3.5% mean ARD due to the BG-to-IG kinetics, and 5.6% mean ARD due to the measurement noise). An important cause of the insufficient CGM calibration is the inaccurate estimation of the sensor background current in calibration, [7] [8] [9] [10] which causes large CGM inaccuracy particularly in hypoglycemia, and as a result, the hypoglycemic BG values are overestimated by CGM readings. [13] [14] [15] This can lead to failure in detection of hypoglycemia, and consequently causes critical situations for the patient. 9, 10, 16 The invivo sources of the sensor background current, which is a glucose-nonspecific current, are 3 main interfering substances in interstitial fluid (ISF) including ascorbic acid, acetaminophen, and uric acid. 7, 10, 11, 17 These 3 components are oxidized and generate current, in the presence of the voltage applied between the sensor electrodes 7, 11 ISIG I I g = + 0 (1) where ISIG (interstitial signal) is the current measured by the sensor, I g is the true glucose current, and I 0 is the sensor background current. It is difficult to directly measure the sensor background current in vivo; 7 therefore, if the current is not negligible, it has to be estimated mathematically by means of a 2-point calibration algorithm where the background current is estimated by measuring the sensor output at 2 or more different BG concentrations and finding the y-intercept at zero glucose level. 3, 7, [17] [18] [19] [20] [21] Although theoretically attractive, estimation of the sensor background current with an acceptable accuracy is difficult to achieve through a 2-point calibration, mainly because of the physiological time lag between BG and IG. 3, 11, 22 The time lag causes a variable gradient between BG and IG. 3, 6, [22] [23] [24] [25] Based on the fact that CGM sensor samples IG, there is also a variable gradient between BG and ISIG. Because of the variable gradient between BG and ISIG, and also considering the fact that ISIG values are calibrated against BG values, a linear calibration with fixed parameters (slope and intercept) has a substantial error in the estimation of the sensor background current. Therefore, the time lag is a major cause of inaccurate estimation of the sensor background current especially if the calibration points are taken at the non-steady state between BG and IG (eg, dropping BG to hypoglycemia, and after a meal), which the effect of lag is maximized. 4, [26] [27] [28] [29] Rebrin et al 13 demonstrated that any mismatch between the true background current and the estimated current by the calibration results in a CGM sensor that underestimates BG values above the calibration point and overestimates the values below the calibration point. Therefore, although theoretically the sensor background current can be estimated by a 2-point calibration, the error of the estimation itself affects the accuracy of the calibrated sensor readings to a large extent. Choleau et al 8 demonstrated that considering zero value for the background current by using a 1-point calibration produces more accurate sensor readings than estimating the current by a 2-point calibration.
In a previous study, 30 we developed a CGM algorithm with the aim of shortening filtering delay, and reducing the BG-CGM deviation in hypoglycemia. We used a 2-point calibration approach to estimate the sensor sensitivity and the sensor background current. We compared our algorithm with an alternative CGM algorithm, using data from 16 type 1 diabetes patients. The results were promising and indicated the potential of our algorithm to improve CGM accuracy.
The aim of the current study is updating the algorithm by using a 1-point calibration approach instead of a 2-point calibration approach, and investigating the effect of this algorithm modification on the CGM accuracy by evaluating the algorithm in a larger number of type 1 diabetes patients.
Subjects and Methods

Subjects
CGM data were collected using the SCGM1 (Roche Diagnostics, Mannheim, Germany), a microdialysis-based CGM system which allows up to 120 hours of 1-minute dialysate glucose measurements. Two centers contributed to the data collection that was part of the clinical in vivo development phase of the SCGM1 system: Medical Department M, Aarhus University Hospital, Denmark, and Profil Institute for Metabolic Research, Neuss, Germany. 31 The data included more than 200 data sets from type 1 and type 2 diabetic patients. In addition to the CGM data, reference values in the form of capillary BG measurements were obtained by nurses up to 20 times per day using a built-in BG meter; each measurement was performed twice for confirmation of the value. Data capture lasted for up to 5 days per patient. The data for the current study were selected from this population using the following criteria: 31 (1) data sets from patients with type 1 diabetes and (2) sufficient technical quality of the data. Applying these inclusion criteria, we retained data sets from 132 type 1 diabetic patients with a total of 14 571 hours of 1-minute CGM data and 18 056 reference-sensor pairs. Reference BG measurements were used for calibration and evaluation of the algorithm. Only the reference BG values within the measurement range of CGM systems (40 ≤ BG ≤ 400) were considered valid for calibration and evaluation of the algorithm. The 2 values at each reference BG measurement instance were averaged before they were used in the algorithm. Table 1 gives the characteristics of the patients enrolled in the study.
Continuous Glucose Monitoring Algorithm
The algorithm includes the main elements in Figure 1 . It operates on the ISIG which is the raw current measured by the CGM sensor with a sampling frequency of 1 per minute. The newly developed algorithm is described in detail in our previous work. 30 Therefore, to keep this section concise, only a brief description of the algorithm is given.
The rate-limiting filter in the first block applies a limit on the signal rate of change, set on a physiological threshold of 4 mg/dl/min. 21, 32 If the rate of change between 2 successive ISIG values exceeds the defined limit, the most recent ISIG value is replaced by a weighted local polynomial regression estimate. 30 In the second block, first, the number of zero crossings (ZCs) of the signal first-order differences is calculated in 5-minute segments of the signal. The signal segment is considered noisy if the number of ZCs is larger than 1. Second, the noisy segments of the signal are filtered by a weighted moving average of order 50. Finally, in the third block, the current measured by the sensor, which is processed in the preceding blocks, is converted into a glucose level (mg/dl). The signal is calibrated by a 2-point calibration approach, coefficients being estimated using robust regression with a bi-square weight function. A maximum of 4 BG-ISIG pairs and a minimum of 2 pairs per day are utilized for calibration, forming the calibration set. The calibration set is corrected for any existing low correlation coefficients between reference BG measurements and ISIG values and also for a low relative standard deviation (RSD) of the BG values. A corrective intercept (CI) as described by Mahmoudi et al 30 is subtracted from the calibrated sensor glucose (SG) to correct the overestimation of BG by CGM in the hypoglycemic range of BG (BG ≤ 70 mg/dl).
SG SG CI
CI is a 2-order polynomial which its value is adjusted with the value of the SG. For other values of SG, CI is zero.
The coefficients a 1 , a 2 , and a 3 are estimated by fitting the 3 following points to equation 3 
Calibration
Basically, 2 types of calibration procedures have been used in the commercial CGM systems. 5 
The sensor sensitivity and the background current are estimated from
When multiple data points are available, a linear regression can be used to fit slope and intercept to the data. Standard linear regression techniques find the m and I 0 that minimize the sum of the squares of the errors (differences between measurements and model predictions).
To upgrade the algorithm, we replaced the 2-point calibration approach in the algorithm with a 1-point calibration approach, and compared the accuracy of this new version of the algorithm with the old version. The other parts of the algorithm remained the same. In the calibration regression, we used the ISIG signal as the independent variable in the regression analysis of the calibration line. The 2 calibration approaches which we compared are given in Table 2 , where
x is the calibrated SG, y is the ISIG signal, a and b are the slope and the intercept of the calibration, respectively, and CI is the corrective intercept.
Performance Measures
Three performance metrics were used to evaluate the performance of the 2 algorithm versions.
Absolute Relative Deviation (ARD)
The ARD was calculated for each patient as the relative deviation of the processed SG values from the paired reference BG measurements.
ARD
SG BG BG i n n number of BG SG pairs
Clarke Error Grid Analysis (EGA)
The often used Clarke EGA introduced by Clarke et al 34 was applied to classify BG-SG pairs into different clinically interpretable categories.
Sensitivity and Specificity of Hypo-and Hyperglycemia
The sensitivity and specificity of the 2 algorithms for hypoglycemia and hyperglycemia detection were measured using the single measurements of reference BG values and their paired SGs. Hypoglycemia and hyperglycemia were defined as single reference BG ≤ 70 mg.dl -1 and > 180 mg.dl -1 respectively. ) which have been affected by CI and transferred to the hypoglycemic range ( 70 > SG ), while they have concurrent hypoglycemic BG level. The specificity of the corrective intercept is the percentage of the non-hypoglycemic SG values which have been affected by CI and not transferred to the hypoglycemic range, and they have concurrent non-hypoglycemic BG level.
We further excluded CI from the 1-point and 2-point calibrations and evaluated the effect on the CGM accuracy, to assess the contribution of CI to the calibration improvement.
Retrospective and Real-Time Estimation of the Sensor Background Current
For retrospective estimation of I 0 , using the complete data set, we fitted the line 
Statistical Analysis
Statistical analyses were performed in MATLAB (version 8.1.0. 604 [R2013a]). The Wilcoxon signed rank test was used to compare the median ARD of the 2 algorithm versions. A value of P < .05 was considered statistically significant for the test. 
Results
For evaluation, the BG measurements were paired with the SG values from the same time. The pairs that were used for calibration were not used for evaluation. The evaluation results are reported pooling all BG-SG pairs. The SCGM1 system has around 31 minutes (SD ± 2 minutes) of micro-dialysis transport lag. 31, 35 We considered this delay fixed throughout the data and corrected for it by shifting the data 31 minutes backward before applying the algorithms. Table 3 demonstrates the median and mean ARD for BG-SG pairs.
There was a statistically significant difference between the median ARD of the algorithm with the 1-point calibration approach and the median ARD of the algorithm with the 2-point calibration approach, in hypoglycemia (P < .0001), hyperglycemia (P < .01), and the full glycemic range (P < .001). No statistically significant difference was perceived in euglycemia (P > .05). Table 4 indicates the results of Clarke EGA obtained from the 2 versions of the algorithm, in hypoglycemia and in all glycemic ranges. Figure 2 depicts the distribution of the BG-SG pairs in the Clarke EGA zones for the 2 algorithms. Figure 3 demonstrates the sensitivity and specificity of hypoglycemia and hyperglycemia detection for the 2 versions of the calibration algorithm. Figure 5 demonstrates the sensitivity and specificity of CI for correction of undetected hypoglycemia.
After exclusion of CI from the 2-point calibration, the median (mean) ARD were 21.2% (32.6%), 10.8% (15.6%), 9.2% (13.0%), and 10.8% (16.3%) in hypoglycemia, euglycemia, hyperglycemia, and the full glycemic range, retrospectively. For the 1-point calibration, exclusion of CI gave the median (mean) ARD of 14.0% (22.1%), 10.7% (15.5%), 8.8% (12.8%), and 10.3% (15.3%), in hypoglycemia, euglycemia, hyperglycemia, and the full glycemic range, respectively. The mean of the real-time estimated I 0 is -3.5 nA (SD ± 12.5), and 95% confidence interval of −27.9, 21.0. The 95% confidence interval contains zero, suggesting that the realtime estimated I 0 is not statistically greater than zero.
Discussion
We compared the accuracy of the 1-point calibration approach with the 2-point calibration approach in our previously published algorithm, by using data from 132 type 1 diabetes patients. Using the 1-point calibration approach reduced the median and mean ARD in hypoglycemia and hyperglycemia, but did not change ARD in euglycemia. Because the sensor background current exacerbates the CGM inaccuracy mainly in hypoglycemia and hyperglycemia, it seems reasonable that any modification in a calibration algorithm, dealing with the estimation of the background current, affects the CGM accuracy mainly in hypoglycemia and hyperglycemia rather than euglycemia. That explains the obtained results in which the 1-point calibration altered the accuracy in hypoglycemia and hyperglycemia, but not in euglycemia. Kovatchev et al 36 evaluated the accuracy of 4 commercially available CGM devices and indicated that the overall mean ARDs of Guardian, Dexcom, Navigator, and Glucoday are 15.2%, 21.2%, 15.3%, and 15.6%, respectively. Although the overall mean ARD of 15.6% in the 1-point calibration achieved in our study is comparable with those results, a direct comparison is hardly possible due to the different study designs. For example, Kovatchev et al 36 reported the use of arterial BG measured by YSI BG analyzer, but we used BG values measured by SMBG meters. A fair comparison of calibration algorithms can be achieved by implementing the algorithms on identical CGM systems worn simultaneously by all subjects.
The overall reduction in the median absolute relative differences (MARD) from 11% in the 2-point calibration to 10.7% in the 1-point calibration may have little impact on a clinician's confidence in the device; however, the large reduction of the hypoglycemia inaccuracy would likely change clinical perception and can influence the CGM-based clinical decision making in hypoglycemia treatment.
The percentage of the CGM readings in zone A of the Clarke EGA in hypoglycemia and in zone A+B in the full glycemic range increased by using a 1-point calibration instead of a 2-point calibration approach. Because the percentage of the sensor readings in the clinically acceptable zones (zone A in hypoglycemia and zone A+B in the full glycemic range) is an indicator of the CGM clinical safety, the results imply that the use of a 1-point calibration approach may enhance the usefulness and the clinical reliability of the real-time CGM, and increase the patients' confidence in the glycemic values measured by the sensor.
Using 1-point calibration increased hypoglycemia sensitivity with 12.9%, and had little impact on hyperglycemia sensitivity. This may originate from the larger effect of the 1-point calibration on ARD in the hypoglycemic range rather than that in the hyperglycemic range. The specificity of both hypoglycemia and hyperglycemia slightly decreased, by replacing the 2-point calibration with the 1-point calibration approach.
Results indicate that, in our algorithm, the 1-point calibration approach has generally higher accuracy than the 2-point calibration approach. This is aligned with the results obtained by Choleau et al 8 who demonstrated that a 1-point calibration approach produces more accurate CGM readings than a 2-point calibration. It is worth pointing out that the slope and the intercept in the calibration algorithm are not solely identified by the sensor sensitivity and the glucose-nonspecific current due to the interfering substances. However, they are mathematical operators, and according to the statistics of a straight line, their precision is dictated by the precision of both the measurement of the sensor output and the SMBG values. It is therefore expected that the precision of the estimated slope and intercept be poorer in the case of a 2-point calibration compared to a 1-point calibration, because of the greater measurement uncertainty in the 2-point calibration. 7, 37 Furthermore, if the calibration points are not taken in steady-state condition, the estimated intercept significantly deviates from the true glucose-nonspecific interfering current. 37 The accuracy of a 2-point calibration may improve by increasing the number of calibration points used to estimate the slope and the intercept in the calibration regression; 38 however, this may not be practical, because the CGM manufacturers strive to keep the number of calibration points as limited as possible.
In the 1-point calibration used in our CGM algorithm, the sensor background current is not considered zero when the calibrated sensor readings are between 70 mg/dl and 85 mg/ dl, and we tried to compensate for the effect of background current by inclusion of CI in the calibration. Correction of the sensor background current in the CGM calibration is also suggested by other researchers. Youssef et al 7 improved the calibration accuracy by correction for the background current in amperiometric glucose sensors. They demonstrated that the use of a background current of 4 nA in the calibration improves the general accuracy in the Guardian® REAL-Time CGM and also reduces the hypoglycemia overestimation and therefore, leads to better hypoglycemia detection. Also in a published patent from the Medtronic, 39 correction for the sensor background current is suggested by inclusion of an offset in the calibration with the 2 levels of zero and 3 nA, depending on the sensor sensitivity; however, the amplitude of this intercept cannot adapt to the glucose level, while CI in our calibration algorithm varies depending on the sensor glucose levels.
Comparing the ARD after excluding CI with the results in Table 3 indicated that for the 2-point calibration, removing CI exacerbates hypoglycemia inaccuracy by 15% increasing of the MARD, and improves euglycemia accuracy by 5% reducing of the MARD. For the 1-point calibration, removing CI exacerbates hypoglycemia inaccuracy by 16% increasing of the MARD, and slightly improves euglycemia accuracy by 7% reducing of the MARD. Because CI acts on the normal SG range ( 70 85 ≤ < SG ), and due to the moderately low specificity of CI ( Figure 5 ), some of the non-hypoglycemic SG values which are transferred to hypoglycemic range by CI may not have concurrent BG values. That is the reason for the slight reduction in euglycemia accuracy by inclusion of CI. However, comparison between the percentage of the MARD increase in hypoglycemia with the percentage of the MARD reduction in euglycemia, after exclusion of CI from the 2 calibration algorithms, suggests that the presence of CI in the calibration may be yet advantageous despite reducing the euglycemia accuracy. The retrospective and real-time estimations of the sensor background current indicated that the 95% confidence intervals contain zero for both estimation methods. This may suggest that the background current can be considered zero, and a simple 1-point approach suffices for calibration. However, this may not apply to other types of CGM sensors.
It should be noted that in addition to the value of the background current and the way it is estimated in calibration, a host of other factors also affects the quality of a 2-point calibration, and consequently the CGM accuracy. These factors concern the reference BG values used for calibration, including calibration timing and the number of reference BG measurements used in the calibration, the glycemic range in which reference BG values fall, the rate of change of reference BG values at the calibration time, and the difference between the 2 reference BG values. 22, 28, 38, 40, 41 The DirectNet study group 38 indicated that the timing of calibration is more influential on the CGM accuracy than the number of BG points used for calibration. It was also demonstrated that CGM accuracy worsens when calibration is performed in the rate-of-change of ±15 mg/ dl/min, suggesting for calibrating in the periods of glucose stability. Aussedat et al 41 introduced a method to identify the 4-min windows of glucose stability in which the sensor signal does not change more than 1%, and also to update calibration when the difference between the two sensor signal values is greater than 2 nA. King et al 40 indicated that if the two reference glucose values in the 2-point calibration differ by > 30 mg/dl, the quality of calibration improves. Zueger et al 42 demonstrated that preprandial calibration compared to postprandial calibration produces more accurate CGM data in euglycemic and hyperglycemic ranges of reference glucose values. based on preprandial reference glucose values results in significantly higher sensor accuracy in hyperglycemia and euglycemia. Iscoe et al 28 indicated that having one of the reference glucose measurements in hypoglycemia reduces the overestimation of hypoglycemic glucose values by sensor.
The reference glucose meters have error compared to gold standard BG assays, for example, laboratory measurements, which also affects the calibration accuracy. In the current study, the accuracy of the BG measurements was not assessed by comparing with a gold standard measurement; however, the authors performed an analysis to indicate the precision of the BG values, by measuring the absolute difference between the 2 capillary BG values taken at each instance. The mean of the absolute differences across the data was 7.7 mg/dl (SD ± 14.3 mg/dl). This may imply that the 2 reference BG values taken at each instance were in reasonable agreement, and therefore a third confirmatory measurement seems unnecessary.
Conclusions
A previously published CGM algorithm was modified by replacing the 2-point calibration approach with the 1-point calibration approach. The results demonstrate that using a 1-point calibration may be superior to a 2-point calibration, in mitigating the insufficiency of the CGM calibration.
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